Pharmaceuticals

CRJZ

Huachun Jiangzhong Q1 2026 Financial Results: Revenue Down, Net Profit Up

CRJZ released FY2026 Q1 earnings on April 24 After-Market (BJT), actual revenue CNY 1.036 B (forecast CNY 1.216 B), actual EPS CNY 0.46 (forecast CNY 0.4548)

CRJZ to Release FY2026 Q1 Earnings on April 25 After-Market (BJT), Forecast Revenue CNY 1.216 B, EPS CNY 0.4548

CRJZ released FY2025 Q4 earnings on March 19 Pre-Market (BJT), actual revenue CNY 1.286 B (forecast CNY 1.616 B), actual EPS CNY 0.35 (forecast CNY 0.2678)

CRJZ released FY2025 Annual Earnings on March 19 Pre-Market (BJT), actual revenue CNY 4.22 B (forecast CNY 4.62 B), actual EPS CNY 1.43 (forecast CNY 1.3801)

China Resources Jiangzhong to release FY2025 earnings on March 20, pre-market (BJT), forecast revenue CNY 4.62 B, EPS CNY 1.3801

JZYY released FY2025 Q3 earnings on October 24 After-Market (BJT), actual revenue CNY 792.05 M (forecast CNY 903.27 M), actual EPS CNY 0.2579 (forecast CNY 0.26)

JZYY released FY2025 9 Months Earnings on October 24 After-Market (BJT), Actual Revenue: CNY 2.933 B, Actual EPS: CNY 1.0784

JZYY to Release FY2025 Q3 Earnings on October 25 After-Market (BJT), Forecast Revenue CNY 903.27 M, EPS CNY 0.2337

JZYY released FY2025 Q2 earnings on August 21 After-Market (BJT), actual revenue CNY 957.02 M (forecast CNY 1.05 B), actual EPS CNY 0.3704 (forecast CNY 0.3865)

JZYY released FY2025 Semi-Annual Earnings on August 21 After-Market (BJT), actual revenue CNY 2.141 B, actual EPS CNY 0.82

JZYY FY2025 Semi-Annual Earnings Release on August 22, 2025, BJT

Jiangzhong Pharmaceutical Participates in Setting Up CR Medicine Innovation Fund

Jiangzhong Pharmaceutical Discloses OTC Sales Performance

CICC gives Jiangzhong Pharmaceutical an outperform rating

Jiangzhong Pharmaceutical Registers 7 New Software Copyrights

Jiangzhong Pharmaceutical Secretary Responds to Investor Dividend Policy Questions

China Resources Pharma Reports Jiangzhong Pharma's Q1 Earnings

Jiangzhong Pharmaceutical 2025 Q1 Revenue Down But Net Profit Up

JZYY released FY2025 Q1 earnings on April 25 After-Market (BJT), actual revenue CNY 1.184 B (forecast CNY 1.216 B), actual EPS CNY 0.45 (forecast CNY 0.422)

03320

600750

China Resources Pharma announced that its subsidiary China Resources Jiangzhong achieved an operating revenue of 5.22 billion (RMB) for the fiscal year 2025, a year-on-year decrease of 4.9%. The net profit attributable to shareholders was 907 million, an increase of 15%, with earnings per share of 1.43 yuan

AASTOCKS

CHINARES PHARMA

China Resources Pharma's subsidiary China Resources Jiangzhong earned 907 million RMB last year, an increase of 15%

China Resources Pharma announced that its subsidiary China Resources Jiangzhong achieved a total operating revenue of RMB 4.22 billion for the fiscal year 2025, a year-on-year decrease of 4.9%. The net profit attributable to shareholders was RMB 906 million, an increase of 15%, with earnings per share of RMB 1.43

China Resources Pharma's subsidiary China Resources Jiangzhong earned 906 million RMB last year, an increase of 15%

According to the Zhitong Finance APP, China Resources Pharmaceutical announced the performance of JZYY for the nine months ending September 30, 2025, with total operating revenue of 2.933 billion RMB, a year-on-year decrease of 6.28%; net profit of 743 million RMB, a year-on-year increase of 6.02%

Zhitong

China Resources Pharmaceutical: JZYY's net profit for the first three quarters is 743 million yuan, an increase of 6.02% year-on-year

On October 24th, JZYY announced that in the third quarter of 2025, it achieved operating revenue of 792 million yuan, a year-on-year decrease of 7.59%; the net profit attributable to shareholders of the listed company was 161 million yuan, a year-on-year increase of 4.70%; basic earnings per share were 0.26 yuan

JZYY: The net profit attributable to the parent company in the third quarter was 161 million yuan, an increase of 4.70% year-on-year

000999

562390

Zhongtai Securities released a research report indicating that the gross profit margin of the Chinese medicine sector is expected to recover in the second half of 2025, mainly due to the digestion of high-priced medicinal materials and alleviated cost pressures. Although OTC demand is relatively weak, leading brand OTC products and innovative pipelines still have advantages. In the first half of 2025, the total revenue of Chinese medicine companies is expected to be 172.9 billion yuan, a year-on-year decrease of 4.95%, with a net profit of 19.1 billion yuan, a year-on-year decrease of 9.31%. Overall, the industry's prosperity is gradually recovering, with slight declines in gross profit margin and net profit margin

CR Sanjiu

Yinhua CSI Chinese Medicine ETF

Zhongtai Securities: The gross profit margin of the Chinese medicine sector is expected to recover in H2 2025, optimistic about leading brands in OTC and innovative pipelines

002145

002895

With the conclusion of the semi-annual report disclosures of listed companies, the second-quarter heavy positions and changes in holdings of brokerage firms have been revealed. In terms of increased holdings, brokerages have shown a strong preference for industries such as basic chemicals, machinery and equipment, automobiles, and pharmaceuticals and biotechnology, with a total of 63 stocks being increased in the second quarter. CNNC TD, New Mileage, JZYY, and Yuntianhua have all received increased positions. Chanhen, Fuan Energy, Ruida Futures, and Zhejiang Huaye have also been favored by at least three brokerages

Wallstreetcn

Ti Chem

Chanhen

The heavy holdings of brokerages in the second quarter have been released, favoring industries such as basic chemicals, machinery and equipment, automobiles, and pharmaceuticals and biotechnology

According to the Zhitong Finance APP, China Resources Pharmaceutical announced the mid-term performance of JZYY for 2025, with total operating revenue of approximately 2.141 billion yuan, a year-on-year decrease of 5.79%; net profit attributable to shareholders of the listed company was approximately 522 million yuan, a year-on-year increase of 5.8%; basic earnings per share were 0.82 yuan, with a cash dividend of 5 yuan (tax included) for every 10 shares

China Resources Pharmaceutical: JZYY's net profit attributable to the parent company in the first half of the year was approximately 522 million yuan, a year-on-year increase of 5.8%

JZYY announced that the company plans to invest 40 million yuan in the China Resources Pharmaceutical Industry Investment Fund Phase II, which has a scale of 1 billion yuan and primarily invests in companies related to the pharmaceutical industry. As a limited partner, JZYY holds a 4% property share in the fund, and the investment will include equity investments and convertible bond investments

JZYY plans to invest 40 million yuan in the China Resources Pharmaceutical Industry Investment Fund Phase II

CICC: Assigns JZYY an initial rating of outperforming the market

CICC

CRJZ(600750.SH)